Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
KLOW Blend is a multi-peptide research formulation commonly described as containing four separate peptides: GHK-Cu, BPC-157, TB-500, and KPV.
The most commonly reported formulation is an 80 mg total blend consisting of approximately:
GHK-Cu – 50 mg
BPC-157 – 10 mg
TB-500 – 10 mg
KPV – 10 mg
Formulations may vary by supplier, so the exact composition and concentration should always be verified against the product documentation and certificate of analysis.
The individual ingredients are studied in preclinical research relating to areas such as collagen and extracellular-matrix remodeling, tissue repair, cell migration, and inflammatory signaling. However, the KLOW combination itself has not been adequately studied in controlled human clinical trials, and the blend should not be marketed as proven to treat injuries, inflammation, disease, or other medical conditions.
Research use only. Not for human or veterinary use.
There is currently no validated human dosing protocol for the KLOW blend, and no FDA-approved administration instructions for the combination.
The exact formulation, purity, storage requirements, and laboratory handling instructions should be obtained from the supplier or manufacturer.
Because the components and concentrations may differ between products, the product should not be presented to customers as having a standardized dose based only on volume in mL.
There is no established duration of results for KLOW Blend.
Because the combination has not been adequately evaluated in controlled human clinical studies, there is no scientifically established timeline for when effects begin, how long they last, or whether any effects are sustained after discontinuation.
Any claims about treatment duration, recovery, skin rejuvenation, anti-inflammatory effects, or tissue repair should be treated as experimental or investigational rather than established clinical outcomes.
KLOW Blend is a multi-peptide research formulation commonly described as containing four separate peptides: GHK-Cu, BPC-157, TB-500, and KPV.
The most commonly reported formulation is an 80 mg total blend consisting of approximately:
GHK-Cu – 50 mg
BPC-157 – 10 mg
TB-500 – 10 mg
KPV – 10 mg
Formulations may vary by supplier, so the exact composition and concentration should always be verified against the product documentation and certificate of analysis.
The individual ingredients are studied in preclinical research relating to areas such as collagen and extracellular-matrix remodeling, tissue repair, cell migration, and inflammatory signaling. However, the KLOW combination itself has not been adequately studied in controlled human clinical trials, and the blend should not be marketed as proven to treat injuries, inflammation, disease, or other medical conditions.
Research use only. Not for human or veterinary use.
There is currently no validated human dosing protocol for the KLOW blend, and no FDA-approved administration instructions for the combination.
The exact formulation, purity, storage requirements, and laboratory handling instructions should be obtained from the supplier or manufacturer.
Because the components and concentrations may differ between products, the product should not be presented to customers as having a standardized dose based only on volume in mL.
There is no established duration of results for KLOW Blend.
Because the combination has not been adequately evaluated in controlled human clinical studies, there is no scientifically established timeline for when effects begin, how long they last, or whether any effects are sustained after discontinuation.
Any claims about treatment duration, recovery, skin rejuvenation, anti-inflammatory effects, or tissue repair should be treated as experimental or investigational rather than established clinical outcomes.